Drug delivery systems (DDS) are designed to improve the pharmacological and therapeutic effect. In the past few decades, there are some problems that impeded applications of particulate DDS have been resolved, with several DDS formulations of anticancer now approved for clinical use. Liposomal nanoparticles (LNs) encapsulating therapeutic agents have been recognized as one of the most advanced classes of DDS. Liposomal nanoparticles (LNs) could encapsulate both conventional anticancer drugs and the new genetic drugs with several properties such as high drug-to-lipid ratio, excellent retention of drug and a long circulation lifetime. These excellent properties of LNs have the potentials to offer new treatments in area of cancer therapy. Here, we will discuss recent advances in this field involving conventional anticancer drugs as well as the new genetic drugs.
Introduction
During the past four decades, the excellent advances have been made in the drug delivery systems (DDSs), with several Liposomal nanoparticles (LNs) currently on the market and many more in clinical trials (1). Liposomal nanoparticles (LNs) with a diameter 100 nm, could encapsulate several therapeutic agents, including conventional anticancer drugs, antibiotics, and the newer classes of genetic drugs (antisense oligonucleotides and small interfering RNAs (siRNA)). LNs are easy to prepare, biocompatible, and can carry both chemotherapeutic and genetic drugs to cancer cells (2-6). Furthermore, LNs have the potential to minimize systemic toxicity through conjugating to a tumor targeting agent in hopes of delivering a cytotoxic payload directly to the cancer cells (7) (8) (9) . These excellent properties of LNs made them to be one of ideal DDSs in future. Here, we will highlight the most recent advances and attempting to anticipate future applications and advances in the areas of liposomal medicines (LNMs). For some types of LNMs, such as those containing peptide and protein drugs are not to be discussed here.
Liposomes were first discovered by Alec D. Bangham (British hematologist) in 1961. Initially, they were used as a model system to study biological membranes. The term liposomes were introduced in 1968 by Bangham (10) . Since then, they became very versatile tools in biology, biochemistry and medicine. Liposomes are Technology in Cancer Research & Treatment, Volume 11, Number 5, October 2012 self-assembling closed colloidal structures composed of lipid bilayers and have a spherical shape in which an outer lipid bilayer surrounds a central aqueous space. The vesicles can differ in size (diameter about 15-3500 nm) and shape (single and fused particles). Nevertheless the stability of these vesicles seems to be the best in a range of about 100-300 nm. In a complete formulation together with further ingredients, other influences like compatibility, concentration of salts, amphiphilics, and lipophilics play an important role. Therefore, it is often very difficult to prove the existence of liposomes (11) (12) (13) (14) (15) (16) . For this reason, there has been an intensive search to increase the encapsulation capacity of liposomes. Efforts were made to add emulsifier to the liposomal dispersions to stabilize higher amounts of lipids. Formulators now know that additional emulsifiers have a weakening effect on the barrier affinity of phosphatidylcholine. In this respect, to make use of nanoparticles consisting of phosphatidylcholine and lipids instead of liposome is one rational consideration. Nanoparticles are a consequence of the observation that oil droplets can fuse with liposomes, when the capacity of bilayers for lipids is exhausted (17).
Nowadays, Liposomal nanoparticles (LNs) have been used to encapsulate both conventional anticancer drugs and the new genetic drugs (Figure 1 ). Generally, Liposomal nanoparticles (LNs) have advantages over polymer-based nanoparticles for the formulation of therapeutics. LNs consist of emulsion-like oil droplets surrounded by a monolayer of phosphatidylcholine. The advantage of nanoparticles is that they allow formulations to tolerate more lipids and remain stable without additional emulsifiers. Furthermore, the lipid bilayer provides a remarkable permeability barrier that defines an internal compartment and is capable of protecting the internal contents. Drugs encapsulated within this lipid bilayer are protected from extra-liposomal reactions that could alter the effectiveness of the drug, such as enzymatic degradation or modification of the drug (18). Moreover, LNs could increase the drug concentration at desired sites of action and reduce systemic levels of the drug and its toxic sequelae in healthy tissues. For other advantages of LNs, we list as below (i) Constant rate of drug delivery, resulting in zero-order release kinetics to maintain a constant therapeutic dose at the site of action. (ii) Reduced clearance, to increase the drug half-life. (iii) Increased drug stability, to reduce degradation and maximize drug action. (iv) Drug delivery across the blood-brain barrier (BBB) and blood-cochlear barrier (3, 18, 19) .
Commonly, LNs accumulated at the disease sites by mediating passive or active targeting way. In passive targeting, as observed with many formulations of conventional anticancer drugs, the drug is released from LNs in the extracellular or intercellular space and taken up into the tumor cell. Several types of diseased tissues, particularly those found in cancer, possess vascular tissue that is porous and rather leaky. The endothelial cells often have large gaps between them that allow LNs with diameters up to 400 nm (20, 21) to extravasate from the blood into the surrounding tissues, where they accumulate. In active targeting, it involves the use of peripherally conjugated targeting moieties for enhanced delivery of nanoparticle systems. Although antibody targeting is regarded as a promising strategy, some groups have reported that antibody targeting does not increase tumor localization, but instead increases internalization in animal models. The targeting moieties are important to the mechanism of cellular uptake. Long circulation times will allow for effective transport of the nanoparticles to the tumor site through the enhanced permeability and retention (EPR; EPR was referred to that solid tumors was able to greatly increased production of a number of permeability mediators with posing unique pathophysiological characteristics that are not observed in normal tissues or organs, such as extensive angiogenesis and hence hypervasculature, defective vascular architecture, impaired lymphatic drainage) effect, and the targeting molecule can increase endocytosis of the nanoparticles. The internalization of nanoparticle drug delivery systems has shown an increased therapeutic effect (6, 22, 23) . If the nanoparticle attaches to vascular endothelial cells via a non-internalizing epitope, high local concentrations of the drug will be available on the outer surface of the target cells.
Liposomal Nanoparticles to Delivery Conventional Anticancer Drugs
Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced technology among the nanomedicine systems developed so far. Liposomes are self-assembling colloid structures composed of lipid bilayers surrounding (an) aqueous compartment (s), and can encapsulate a wide variety of (chemo) therapeutic agents. Myocet and Doxil were approved among the first of such lipid self assemblies (Table I) . Both products contain doxorubicin, but differ particularly in the presence of a 'stealth' coating: the former refers to doxorubicin entrapped in uncoated liposomes, and the latter to liposomes surface-modified (or 'sterically stabilized') with poly (ethylene glycol) (PEG) to reduce rapid recognition by the reticuloendothelial system, and thereby to prolong circulation time.
There are also some other examples of LNs for conventional small-molecule drugs (13, 19, (24) (25) (26) (27) (28) (29) (30) . For example, LNs Vincristine is a microtubule inhibitor that acts in the M phase of the cell cycle and is one of the most widely used anticancer drugs (31) (32) (33) (34) (35) . The L1210 and P388 murine leukemia models or the A431 human squamous-cell carcinoma model, formulations of vincristine with progressively slower release rates converted the drug from being essentially inactive to producing 100% cures (36). This dependence on release rates is consistent with the fact that prolonged exposure of cells to cell cycle-specific agent's results in greater cell killing in vitro and enhanced antitumor activity in vivo (37).
In active drug targeting, targeting ligands are attached to drugs and drug delivery systems to act as homing devices for binding to receptor structures expressed at the target site (38). Antibody-drug conjugates targeted to, for example, CD20, CD25 and CD33, which are (over)expressed in non-Hodgkin's lymphoma, T-cell lymphoma and acute myeloid leukaemia, respectively, have been successfully used for delivering radionuclides (Zevalin), immunotoxins (Ontak) and antitumour antiobiotics (Mylotarg) more selectively to tumour cells (39) (40) (41) (42) (43) (44) .
Liposomal Nanoparticles to Delivery siRNA Drugs
Small interference RNA (siRNA) was discovered as 21-23 nucleotide RNA duplexes, which may well be one of the transforming events in biology in the past decade. Production of small siRNA that bind to and induce the degradation of specific endogenous mRNAs is now recognized as a mechanism that is widely employed by eukaryotic cells to inhibit protein production at a posttranscriptional level. In cancer cells, protooncogenes have frequently been activated by various mechanisms, producing oncogenes that act in a dominant fashion (5, 45, 46) . The goals for RNA interference (RNAi) approaches for cancer therapy are therefore to knock out the expression of a cell cycle gene and/or an anti-apoptotic gene in cancer cells thereby stopping tumor growth and killing the cancer cells. Recently, the focus of research involving this approach has shifted from siRNA to a new, exciting class of siRNA drugs delivery system known as LNs (liposomal nanoparticles). When the LNs encapsulate siRNA, the particles are commonly known as stabilized nucleic acid lipid particles, or SNALPs. Several recent studies highlight the therapeutic potential of SNALPs and RNAi in the treatment of a variety of diseases, especially for cancer treatment. A particularly elegant example comes from a recent article describing a new approach for the treatment of ovarian cancer tumors in mice, based on the silencing of the focal adhesion kinase (FAK). The siRNA of FAK can be attacked with LNs which penetrates deeply into the tumor. Mice infected with three human ovarian cancer cell lines derived from women with advanced cancer were treated for 3-5 weeks. They received LNs that contained either the FAK siRNA, a control siRNA, or were empty. Some mice received siRNA liposomes plus the chemotherapy docetaxel (47, 48) . Mice receiving the FAK-silencing liposome had reductions in mean tumor weight ranging from 44 to 72 percent compared with mice in the control groups. Combining the FAK-silencing liposome with docetaxel boosted tumor weight reduction to the 94-98 percent range (49, 50) .
Liposomal Nanoparticles to Delivery Antisense Oligonucleotide Drugs
Antisense therapy has been investigated extensively over the decades because its ease of design and low cost. In general, antisense oligonucleotides (ODNs) are single-stranded DNA molecules with 13-25 nucleotides. Antisense oligonucleotides could inhibit target gene expression by binding the start location of mRNA translation inside cells to block translation of target mRNA into protein. However, free ODNs are degraded in the circulation and are not taken up readily into target cells. Thus, LNs (Liposomal nanoparticles) were seemed as idea candidates for ODNs drugs encapsulation. In our recently studies, we packaged the ODNs-Midkine with LNs to enhance the ODNs-Midkine penetrating into cells and stabilizing them (51). Evidence from our experiments showed that LNs packaged with antisense ODNs-Midkine could suppress hepatocellular carcinoma cancer (HCC) growth both in vitro and in vivo. In addition, the data also indicated that nanoliposomes could effectively delivered antisense ODNs-Midkine and showed less systematic toxicity. Consequently, nanoliposomes incorporated with antisense ODNs-Midkine should represent an effective and less toxic approach for treatment of HCC, and potentially, other tumor types (52, 53) .
Previously, David et al. indicated that ionizable aminolipid (positively charged in acidic buffer solutions), DODAP (1,2-dioleoyl-3-[dimethylamino] propane), to facilitate efficient encapsulation of antisense oligonucleotides in lipid vesicles. The advantage of this ionizable aminolipid is that it can subsequently be rendered neutral at physiological pH. This is essential because when delivery systems bearing a net cationic charge are administered intravenously, they exhibit rapid plasma clearance, distribute into the lung, liver, and spleen (54-57), and often exhibit liver and hemodynamic toxicities such as activation of complement and prolongation of clotting times (58) . They also used a PEG-lipid, PEGceramide, to sterically stabilize the liposomes and thereby prolong their circulation lifetimes (59, 60) .
Subsequent studies revealed that LNs encapsulating CpG ODNs led to a profound stimulation of the immune system, with release of cytokines and activation of natural killer (NK) cells. In retrospect, this should not have been surprising. The ability of bacterial and viral DNA to stimulate an innate immune response with release of inflammatory cytokines and interferon is well known. The fact that LN-CpG ODNs are capable of acting as potent immunostimulatory agents suggests a variety of exciting applications for these agents. If this were to hold true in humans, LNs could have significant potential for vaccine development, expansion and activation of the NK cell population, and enhanced homing of NK cells to tumor sites. To explore this further, a liposome formulation, INX-0167, was developed and optimized to generate the strongest possible sequence-specific innate immune response. This was used to examine the immunopotency of INX-0167 and its ability to act as a vaccine adjuvant when administered subcutaneously with tumor-associated adjuvants. It was observed that LN-CpG ODNs were able to assist adaptive immune responses against coadministered tumor-associated antigens, inducing effective antitumor activity in a number of murine tumor models (38, 61, 62) .
Conclusion and Perspectives
Liposomal nanoparticles may be an effective carrier to deliver anticancer agents to tumors. Anti-cancer LNs drugs are currently being marketed in liposome delivery systems. New Liposomal drugs targeting cancer like Liposomal Cisplatin (Lipoplatin) (Lipoplatin of Regulon Inc.) has received Orphan Drug designation for Pancreatic Cancer. Liposomal nanoparticles drug delivery systems (DDS) would have a bright future as pharmaceuticals for several reasons. First, features such as the passive-targeting effect can substantially enhance the amount of drug at disease sites such as tumors and sites of infection and inflammation. Second, LNs could be ignored by the body's immune system, specifically, the cells of reticuloendothelial system (RES). These liposomes are known as "stealth liposomes", and are constructed with PEG (Polyethylene Glycol) studding the outside of the membrane. The PEG coating, which is inert in the body, allows for longer circulatory life for the drug delivery mechanism. Third, Liposomal nanoparticles could load many of the potential new pharmaceuticals arising from advances in biotechnology are macromolecules such as proteins, peptides, oligonucleotides, and plasmids (63-69). Future studies need to evaluate the mechanism of clearance of liposomal and nanoparticle drug formulations and the factors associated with pharmacokinetic variability (1, 61, 70-73).
